

## News Release

October 16, 2023  
Carna Biosciences, Inc.

### **Announcement of Clinical Trials.gov Registration for GS-9911 Phase 1 Study**

Gilead Sciences, Inc. (Gilead, California, U.S.A.) has developed GS-9911 from the lipid kinase DGK $\alpha$  inhibitor program in-licensed from Carna Biosciences, Inc. and has been preparing for clinical trials. The information for the GS-9911 Phase 1 study in patients with solid tumors has been registered on Clinical Trials.gov.

Official Title	A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
ClinicalTrials.gov ID	NCT06082960
Sponsor	Gilead Sciences

<https://clinicaltrials.gov/study/NCT06082960?term=Gilead%E3%80%80GS9911&rank=1>

Contact:

Corporate Planning

Carna Biosciences, Inc.

TEL: +81-78-302-7075

<https://www.carnabio.com/english/>